Peptide News Digest

Jerome Adams Pitches a Regulated 503A Middle Path for Peptides, Medicare GLP-1 Bridge Denials Trace to a Billing Code, Lantheus Draws an Edotreotide CRL

Jerome Adams pitches a regulated 503A middle path for peptides, Medicare GLP-1 Bridge denials trace to a billing code, and Lantheus draws an edotreotide CRL.

3 stories · Covering regulatory, industry

Editor's Note

A quiet stretch after the July 4 holiday produced three developments worth reading closely, each about how peptides reach patients. The compounding-policy debate moved past weeks of critic-chorus commentary when former Surgeon General Jerome Adams laid out a concrete alternative in STAT: neither an outright ban nor unrestricted access, but supervised 503A dispensing with clinician gatekeeping and outcome tracking, three weeks before the July 23-24 PCAC vote. On the coverage side, the Medicare GLP-1 Bridge closed its first week with eligible seniors turned away at pharmacy counters, and the cause was plumbing rather than policy: claims routed to a patient's normal Part D plan bounce unless they carry BIN 028918 and PCN MEDDGLP1BR. Lantheus's complete response letter for its gallium-68 edotreotide imaging kit rounds out the theme from the manufacturing side, a reminder that even a peptide product with clean trial data can stall on a contract facility's inspection.

Regulatory

Former US Surgeon General Jerome Adams Proposes a Regulated Middle Path for Peptides in STAT: Supervised 503A Dispensing, Clinician Gatekeeping, Informed Consent, and Outcome Tracking

Writing in STAT on July 6, Jerome Adams, the 20th US Surgeon General, argues the FDA should reject both an outright ban and unrestricted access ahead of the July 23-24 Pharmacy Compounding Advisory Committee vote. He proposes allowing select peptides through licensed 503A pharmacies under strict quality controls, requiring clinician evaluation and informed-consent documentation, and mandating real-world outcome tracking to build the safety and efficacy data that gray-market 'research use only' products never generate. The piece notes acting FDA commissioner Kyle Diamantas and a follow-up review expected before February 2027.

#jerome-adams #fda #pcac #503a #peptide-compounding #surgeon-general
Industry

Five Days Into the Medicare GLP-1 Bridge, Eligible Seniors Are Being Denied at the Pharmacy Over a Billing Disconnect, Not Eligibility

A Medical Daily report on July 6 found that eligible Part D beneficiaries are walking away from pharmacy counters without their GLP-1 prescriptions five days after the Bridge launched July 1. The rejections stem from a technical routing problem: when a pharmacy submits the claim through a patient's normal Part D plan, it is automatically denied. The fix is to route the claim through Humana's central processor using BIN 028918 and PCN MEDDGLP1BR, a detail many patients and pharmacists were unprepared for.

#medicare-glp-1-bridge #humana #pharmacy-claims #bin-pcn #prior-authorization #cms
Regulatory

Lantheus Receives FDA Complete Response Letter for LNTH-2501 (Gallium-68 Edotreotide) PET Imaging Kit Over Third-Party Manufacturing Deficiencies

On June 26, Lantheus disclosed a complete response letter for LNTH-2501, its gallium-68 edotreotide PET diagnostic kit for locating somatostatin-receptor-positive neuroendocrine tumors in adults and children. The FDA cited unresolved inspection conditions at the third-party facility that manufactures the drug product and could not approve by the June 29 PDUFA date. The agency raised no concerns about the clinical data, safety, or efficacy. CEO Mary Anne Heino said the feedback 'relates solely to our third-party manufacturer, and not to the clinical performance of the product.'

#lantheus #edotreotide #radiopharmaceutical #neuroendocrine-tumors #somatostatin #fda-crl